Lupin taps external funding for R&D of biosimilars in FY18

Biosimilars are copies of innovative biologic drugs and are made from living cells

Lupin, which will file its first biosimilar Etanercept in Europe and Japan in FY18, has tied up with a financial company to fund the research and development of the drug.

The drug-maker did not respond to an email on the issue and has not disclosed the financial company. 

“We have not changed any of our focus on the R&D front. We are actively pursuing the complex generic pipeline,” Chief Executive Officer Vinita Gupta told analysts last month. “What we have done for some of the risky projects (is) we have opted to get a financing partner. We felt given the market evolution